Share This Page
Drugs in ATC Class J04AK
✉ Email this page to a colleague
Drugs in ATC Class: J04AK - Other drugs for treatment of tuberculosis
| Tradename | Generic Name |
|---|---|
| RIFATER | isoniazid; pyrazinamide; rifampin |
| PYRAZINAMIDE | pyrazinamide |
| ETHAMBUTOL HYDROCHLORIDE | ethambutol hydrochloride |
| MYAMBUTOL | ethambutol hydrochloride |
| SIRTURO | bedaquiline fumarate |
| PRETOMANID | pretomanid |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class J04AK: Other Drugs for Tuberculosis
What Are the Key Market Drivers for Drugs in ATC Class J04AK?
The ATC classification J04AK encompasses drugs specifically used for tuberculosis (TB) treatment that do not fall into first-line anti-TB agents (J04A). These drugs include second-line agents, repurposed drugs, and novel agents aimed at drug-resistant TB cases.
Growth Factors:
- Rising incidence of multi-drug resistant TB (MDR-TB) and extensively drug-resistant TB in high-burden countries. WHO reports 450,000 MDR-TB cases globally in 2021 [1].
- Increased funding from global health organizations like Global Fund and WHO for TB research and drug development.
- Advances in drug discovery platforms leading to novel compounds targeting resistant strains.
- Implementation of shorter, more effective regimens that incorporate J04AK drugs.
Market Challenges:
- The emergence of resistance to existing second-line drugs complicates therapy.
- Limited pipeline of new drugs due to scientific and regulatory hurdles.
- High development costs and lengthy clinical trial processes for novel TB drugs.
- Pricing and access issues in low-resource settings.
Market Size Estimates:
- The global TB drugs market was valued at USD 250 million in 2020, with an expected CAGR of 4% [2].
- J04AK drugs comprise a smaller share, estimated at 15% of total TB drug sales, but expected to grow as drug resistance expands.
How is the Patent Landscape Structured?
Patent activity in J04AK reflects the advanced state of R&D and the strategic importance of resistant TB therapy.
Key Patent Trends
- Increased patent filings from major pharmaceutical companies and biotech firms focusing on novel second-line agents, repurposed drugs, and combination therapies.
- Filing peaks observed between 2010-2015, coinciding with the launch of new TB frameworks and funding initiatives.
- Rapid patent expiration for some older drugs, creating opportunities for generic manufacturers.
Major Patent Holders and Patent Types
| Patent Holder | Key Patents | Focus Area | Filing Timeline |
|---|---|---|---|
| Johnson & Johnson | "Bedaquiline" (J04AK11/00) | Diarylquinolines | 2005–2010 |
| Otsuka Pharmaceutical | "Pretomanid" (J04AK09/00) | Nitroimidazoles | 2008–2014 |
| Tuberculosis Research Foundation | "Linezolid compositions" | Oxazolidinones | 2000–2009 |
| Novartis | "Benzothiazinone derivatives" | Novel Diaryl compounds | 2012–2018 |
Patent Expiration and Challenges
- Many patents filed in the late 2000s are now approaching expiry (20-year term from filing date), opening markets for generics.
- Patent litigations and licensing agreements influence market entry strategies.
- Some compounds face patent thickets, affecting development timelines of biosimilars or combination drugs.
Regulatory and IP Considerations
- Patents on compound formulations and methods of use are dominant.
- Regulatory pathways for repurposed drugs are evolving, sometimes allowing data exclusivity that extends market rights despite patent expiration.
- Patent challenges are common in jurisdictions with strong patent protection laws, notably the US, EU, and India.
What Are the Leading Companies Developing J04AK Drugs?
| Company | Drugs | Development Stage | Notable Patents | Focus Area |
|---|---|---|---|---|
| Johnson & Johnson | Bedaquiline | Approved (2012) | Multiple patents | Diarylquinolines |
| Otsuka | Pretomanid | Approved (2019) | Several patents | Nitroimidazoles |
| Lupin | Innovative compounds | Phase II/III | Pending filings | Second-line agents |
| Novartis | Benzothiazinones | Preclinical | Patents filed (2012–2018) | Novel antimycobacterials |
What Are the Trends in the R&D Pipeline?
- Increased focus on drug combinations (e.g., BPaL regimen combining bedaquiline, pretomanid, linezolid).
- Exploration of host-directed therapies alongside antimicrobial agents.
- Development of drugs targeting dormant bacteria and biofilms.
- Integration of nanotechnology and drug delivery platforms.
Summary of Patent Filing & Market Opportunities
- Patent activity peaked between 2008 and 2015, primarily driven by novel compounds and combination therapies.
- Expiring patents create opportunities for generic manufacturers, especially in low- and middle-income countries (LMICs).
- R&D pathways focus on overcoming resistance, shortening treatment durations, and improving safety profiles.
- Market expansion hinges on regulatory approvals, patent statuses, and access programs.
Key Takeaways
- The market for J04AK drugs is driven by the rise of resistant TB strains, with a significant pipeline of novel compounds under development.
- Patent landscape features a mix of active filings by established pharma and academic institutions, with many patents expiring or about to expire.
- Entry barriers include scientific challenges and patent thickets, but opportunities exist through patent expirations and combination therapies.
- Product innovation targets reducing treatment durations, improving efficacy against resistant strains, and enabling more affordable generic options.
FAQs
1. What are the most promising new drugs within ATC class J04AK?
Bedaquiline and pretomanid lead R&D efforts, both receiving regulatory approval and integrating into combination therapy regimens.
2. How does patent expiration impact drug availability in this class?
Expired patents facilitate generic manufacturing, potentially lowering prices and increasing access in LMICs.
3. Which regions hold the most patents for J04AK drugs?
The US, Europe, and India have the highest patent activity, reflecting regulatory and market development priorities.
4. Are there significant regulatory hurdles for J04AK drugs?
Yes, especially for novel compounds and repurposed drugs, requiring extensive clinical data under stringent protocols.
5. What opportunities exist for new entrants in this market?
Filing for patents on combination therapies, novel mechanisms targeting resistant strains, or reformulations can achieve market entry.
References
[1] World Health Organization. (2022). Global tuberculosis report 2022. WHO.
[2] MarketsandMarkets. (2021). Tuberculosis Drugs Market by Drug Class, Route of Administration, Distribution Channel, and Region - Global Forecast to 2026.
More… ↓
